
Browsing restrictions can be lifted for a fee.
The latest data point for Pfizer's (PFE) Current Contract Liabilities in Q4'25 stands at $784M USD, reflecting a continued decline from the previous quarter's $924M USD and marking the lowest level in the observed period. Over the timeframe from Q1'23 to Q4'25, the chart exhibits an overall downward trend in Current Contract Liabilities, starting at a peak of $2.7B USD in Q4'23 before steadily decreasing with intermittent fluctuations, such as a temporary rise to $2.528B USD in Q2'24 followed by sharp drops exceeding 40% in Q4'24 and Q1'25. This bar chart highlights significant volatility in the early quarters, with liabilities averaging around $1.8B USD through 2023, but accelerating declines in 2025 suggest potential shifts in revenue recognition or contract fulfillment dynamics, warranting monitoring for underlying business impacts.